The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized Double-blind, Placebo-controlled Trial
Primary Purpose
Gastric Cancer, Gastric Adenoma
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Saline
Bupivacaine + saline
Bupivacaine + triamcinolone acetonide
Sponsored by
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring bupivacaine,, triamcinolone acetonide,, endoscopic, submucosal, dissection, Patients
Eligibility Criteria
Inclusion Criteria:
- Age, between 20 and 80
- Patients who were scheduled to undergo ESD for gastric epithelial neoplasm at Severance Hospital between July 2012 and April 2013
Exclusion Criteria:
- Not providing written informed consent
- A history of any cardiac arrhythmias
- Current or regular use of analgesic medication for other indications
- Known other disease such as peptic ulcer disease or reflux esophagitis which could induce upper gastrointestinal pain
- Multiple lesions requiring ESD in a single patient
- Evidence of infectious disease or antibiotics therapy within 7 days prior to enrollment
- Participation in another clinical trial within 30 days prior enrollment
- Current pregnancy or breast feeding.
Sites / Locations
- Severnace Hospital, Yonsei University Health System
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Active Comparator
Arm Label
Control group
Bupivacaine only group
Bupivacaine with triamcinolone group
Arm Description
Outcomes
Primary Outcome Measures
Present Pain Intensity (PPI) score
Present Pain Intensity (PPI) score at 6 hour after endoscopic submucosal dissection (ESD) is assessed
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01961752
Brief Title
The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized Double-blind, Placebo-controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
April 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yonsei University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Although pain is a common complication of endoscopic submucosal dissection (ESD), management strategies are inadequate. bupivacaine is used for visceral pain control in chronic pain and in pain associated with surgery in clinical practice. Further, triamcinolone, a type of steroid, is often mixed with bupivacaine to lengthen the analgesic effect. The aim of this study was to evaluate the efficacy of topical bupivacaine and triamcinolone acetonide for abdominal pain relief and as a potential method of pain control after ESD for gastric neoplasia. We hypothesized that topical bupivacaine and/or triamcinolone acetonide injection after ESD would be effective for pain relief. For this, we designed randomized, double-blind, placebo-controlled trial. Eligible patients with early gastric neoplasm were randomized into one of three groups: bupivacaine (BV) only, bupivacaine with triamcinolone (BV-TA), or placebo. To evaluate the pain after ESD, the Present Pain Intensity (PPI) score and the Short-Form McGill Pain Questionnaire (SF-MPQ) were used to evaluate pain at 0, 6, 12 and 24 h after ESD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer, Gastric Adenoma
Keywords
bupivacaine,, triamcinolone acetonide,, endoscopic, submucosal, dissection, Patients
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
111 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Title
Bupivacaine only group
Arm Type
Experimental
Arm Title
Bupivacaine with triamcinolone group
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Saline
Intervention Description
All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine + saline
Intervention Description
All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine + triamcinolone acetonide
Intervention Description
All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
Primary Outcome Measure Information:
Title
Present Pain Intensity (PPI) score
Description
Present Pain Intensity (PPI) score at 6 hour after endoscopic submucosal dissection (ESD) is assessed
Time Frame
at 6 hour after endoscopic submucosal dissection (ESD)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age, between 20 and 80
Patients who were scheduled to undergo ESD for gastric epithelial neoplasm at Severance Hospital between July 2012 and April 2013
Exclusion Criteria:
Not providing written informed consent
A history of any cardiac arrhythmias
Current or regular use of analgesic medication for other indications
Known other disease such as peptic ulcer disease or reflux esophagitis which could induce upper gastrointestinal pain
Multiple lesions requiring ESD in a single patient
Evidence of infectious disease or antibiotics therapy within 7 days prior to enrollment
Participation in another clinical trial within 30 days prior enrollment
Current pregnancy or breast feeding.
Facility Information:
Facility Name
Severnace Hospital, Yonsei University Health System
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
19890693
Citation
Kiriyama S, Oda I, Nishimoto F, Mashimo Y, Ikehara H, Gotoda T. Pilot study to assess the safety of local lidocaine injections during endoscopic submucosal dissection for early gastric cancer. Gastric Cancer. 2009;12(3):142-7. doi: 10.1007/s10120-009-0514-y. Epub 2009 Nov 5.
Results Reference
background
PubMed Identifier
25060683
Citation
Kim B, Lee H, Chung H, Park JC, Shin SK, Lee SK, Lee YC. The efficacy of topical bupivacaine and triamcinolone acetonide injection in the relief of pain after endoscopic submucosal dissection for gastric neoplasia: a randomized double-blind, placebo-controlled trial. Surg Endosc. 2015 Mar;29(3):714-22. doi: 10.1007/s00464-014-3730-4. Epub 2014 Jul 25.
Results Reference
derived
Learn more about this trial
The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized Double-blind, Placebo-controlled Trial
We'll reach out to this number within 24 hrs